Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Statkevich

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 20, 2002
Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjectsJames E Patrick, Teddy Kosoglou, Kathe L Stauber, et al.
Clinical Breast Cancer|January 8, 2014
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancerMonica M Mita, Anil A Joy, Alain Mita, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjectsXia Chen, Teddy Kosoglou, Paul Statkevich, et al.
Journal of Clinical Pharmacology|February 24, 2006
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patientsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
British Journal of Clinical Pharmacology|September 19, 2002
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatinTeddy Kosoglou, Ingo Meyer, Enrico P Veltri, et al.
Journal of Clinical Pharmacology|February 24, 2006
Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjectsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancerJoe J Stephenson, John Nemunaitis, Anil A Joy, et al.
Cancer|July 20, 2005
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinomaEdward S Kim, Merrill S Kies, Frank V Fossella, et al.
Cancer Investigation|October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 20, 2002
Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjectsJames E Patrick, Teddy Kosoglou, Kathe L Stauber, et al.
Clinical Breast Cancer|January 8, 2014
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancerMonica M Mita, Anil A Joy, Alain Mita, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjectsXia Chen, Teddy Kosoglou, Paul Statkevich, et al.
Journal of Clinical Pharmacology|February 24, 2006
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patientsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
British Journal of Clinical Pharmacology|September 19, 2002
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatinTeddy Kosoglou, Ingo Meyer, Enrico P Veltri, et al.
Journal of Clinical Pharmacology|February 24, 2006
Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjectsArthur J Bergman, Joanne Burke, Patrick Larson, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancerJoe J Stephenson, John Nemunaitis, Anil A Joy, et al.
Cancer|July 20, 2005
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinomaEdward S Kim, Merrill S Kies, Frank V Fossella, et al.
Cancer Investigation|October 21, 2011
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancerNan Soon Wong, Kellen L Meadows, Lee S Rosen, et al.
Pageof 5